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Abstract
In vivo GITR ligation has previously been shown to augment T-cell-mediated anti-tumor immunity, yet the underlying
mechanisms of this activity, particularly its in vivo effects on CD4+ foxp3+ regulatory T cells (Tregs), have not been fully
elucidated. In order to translate this immunotherapeutic approach to the clinic it is important gain better understanding of
its mechanism(s) of action. Utilizing the agonist anti-GITR monoclonal antibody DTA-1, we found that in vivo GITR ligation
modulates regulatory T cells (Tregs) directly during induction of melanoma tumor immunity. As a monotherapy, DTA-1
induced regression of small established B16 melanoma tumors. Although DTA-1 did not alter systemic Treg frequencies nor
abrogate the intrinsic suppressive activity of Tregs within the tumor-draining lymph node, intra-tumor Treg accumulation
was significantly impaired. This resulted in a greater Teff:Treg ratio and enhanced tumor-specific CD8+ T-cell activity. The
decreased intra-tumor Treg accumulation was due both to impaired infiltration, coupled with DTA-1-induced loss of foxp3
expression in intra-tumor Tregs. Histological analysis of B16 tumors grown in Foxp3-GFP mice showed that the majority of
GFP+ cells had lost Foxp3 expression. These ‘‘unstable’’ Tregs were absent in IgG-treated tumors and in DTA-1 treated TDLN,
demonstrating a tumor-specific effect. Impairment of Treg infiltration was lost if Tregs were GITR
2/2, and the protective
effects of DTA-1 were reduced in reconstituted RAG1
2/2 mice if either the Treg or Teff subset were GITR-negative and
absent if both were negative. Our results demonstrate that DTA-1 modulates both Teffs and Tregs during effective tumor
treatment. The data suggest that DTA-1 prevents intra-tumor Treg accumulation by altering their stability, and as a result of
the loss of foxp3 expression, may modify their intra-tumor suppressive capacity. These findings provide further support for
the continued development of agonist anti-GITR mAbs as an immunotherapeutic strategy for cancer.
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Introduction
GITR (glucocorticoid-induced tumor necrosis factor (TNF)
receptor, or TNFRSF18) is a type I transmembrane protein with
homology to other TNF receptor family members such as OX40,
CD27, and 4-1BB.[1] GITR is normally expressed at low levels on
resting CD4+foxp3- and CD8+ T cells, but is constitutively
expressed at high levels on CD4+CD25+foxp3+ regulatory T cells
(Tregs). Expression increases on all 3 subpopulations following T-
cell activation. GITR ligation provides a co-stimulatory signal that
enhances both CD4+ and CD8+ T-cell proliferation and
effector functions, particularly in the setting of suboptimal TCR
stimulation.[2,3,4,5] In addition, co-stimulation through GITR
has been shown to make naı ¨ve or effector T cells (Teffs) resistant to
the suppressive effects of Tregs in vitro, and can enhance auto-
reactive, allo-reactive, and anti-viral T-cell responses in
vivo.[2,6,7,8,9,10,11,12,13] This makes targeting GITR a poten-
tial immunotherapeutic approach to cancer treatment.
Recently, we and others have demonstrated that in vivo GITR
ligation using an agonist anti-GITR mAb, DTA-1, can augment
anti-tumor T-cell responses and induce tumor rejection in B16
melanoma and other murine models.[14,15,16,17,18,19] Howev-
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rejection remain unclear. The direct co-stimulation of tumor-
specific effector CD4+ and CD8+ T cells (Teffs) has been
demonstrated, particularly in combination with active vaccination
[16,17,19]; yet, the in vivo effects of DTA-1 on Tregs have not
been well-defined. In fact, prior in vitro studies have suggested that
the ability of DTA-1 to ‘‘block’’ Treg suppressive activity is due
solely to its co-stimulation of Teffs, with little to no impact on
Tregs themselves.[6]
In this study, we demonstrate that when used as a monotherapy,
DTA-1 modulates both Tregs and Teff during treatment of B16
melanoma. In addition, GITR expression by both Teffs and Tregs
was needed for the full effects of DTA-1. We show that while in
vivo GITR ligation does not globally abrogate Treg suppressive
activity, it does impair Treg tumor infiltration and leads to loss of
foxp3 expression within intra-tumor Tregs, suggesting a localized
abrogation of suppression. The net result is an augmented intra-
tumor Teff:Treg ratio and greater Teff activation and function
within the tumor.
Results
GITR expression is upregulated on tumor-infiltrating
Tregs and CD8+ T cells during B16 melanoma growth
We have shown previously that in vivo GITR ligation by DTA-
1 can induce rejection of B16 melanoma tumors when
administered multiple times starting 1 day after tumor challenge
[18]. Although we established that DTA-1 can cure very early
melanoma tumors, our prior research did not differentiate its
contribution to the priming phase versus the effector phase of the
immune response. Therefore, to more fully comprehend the
mechanisms of GITR ligation therapy, we examined the effects of
a single dose of DTA-1 at different time points post-tumor
challenge to understand the consequences of ligation at distinct
phases of the immune response. We found that 1 mg of DTA-1 on
day 4 of tumor growth led to long-term tumor-free survival in 50–
60% of C57BL/6 mice (Figures 1A, 1B). As in other tumor models
[15], DTA-1 was more effective when given after several days of
tumor growth, with nearly twice as many mice treated on day 4
rejecting tumors compared with mice treated on the day of tumor
inoculation (Figure S1).
This suggests that GITR ligation therapy in B16 requires
initiation of priming, which correlates with in vitro data showing
that upregulation of GITR expression on T cells requires 48–
72 hours after TCR-mediated activation [7,13]. Thus, we
hypothesized that the greater efficacy on day 4 was due, in part,
to increased GITR expression on tumor-activated T cells,
providing a more abundant target for ligation by the agonist
antibody. In fact, we found that by day 4 after B16 inoculation,
GITR expression was significantly higher on tumor-infiltrating
CD8+ and Treg cells than on these populations in the spleen or
tumor-draining lymph node (TDLN) (Figure 1C). This increased
Figure 1. Upregulation of GITR expression correlates with optimal timing of single dose DTA-1 therapy. A and B. C57BL/6 mice (n=10/
group) were challenged intradermally with 50,000 B16 melanoma cells and treated with 1 mg DTA-1 or rat IgG i.p. on day 4 after tumor challenge.
Tumor survival (A) and mean tumor diameter + SEM over time is depicted (B) C. Untreated mice (n=3/group) bearing 4 day-old B16 matrigel tumors
(500,000 cells) were sacrificed and lymphocytes isolated from spleens (S), tumor-draining lymph nodes (DLN), and tumors (T), were stained for CD4,
CD8, foxp3, and GITR. Mean GITR fluorescence intensity (MFI) and SEM within each T cell subset is depicted.
doi:10.1371/journal.pone.0010436.g001
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7 and 14 of tumor growth (data not shown). However, in contrast
to the fibrosarcoma or colon carcinoma models previously
reported [15,17], as well as to our experience in an A20
lymphoma model (Cohen A, unpublished data), starting treatment
with DTA-1 on day 7 or later was generally ineffective (Figure S1).
This demonstrates that optimal timing of in vivo GITR ligation
likely varies according to strain and the underlying immunoge-
nicity and aggressiveness of the tumor subtype.
In vivo GITR ligation does not systemically alter capacity
of Tregs to suppress or Teffs to resist suppression
To investigate the cell-intrinsic effects of DTA-1, we next
explored how agonist anti-GITR mAb might be modulating Teff
and Treg function. Highly purified Tregs were isolated from
tumor-draining lymph nodes (TDLN) of B16-bearing foxp3
GFP
mice [20] after treatment with DTA-1 or IgG, and tested for their
ability to suppress proliferation of CD8+ Teffs isolated from the
same TDLN. Consistent with prior in vitro [6] and in vivo [17]
studies, DTA-1-treated Tregs maintained suppressive capacity
(Figure 2). In addition, neither in vitro nor in vivo GITR ligation
on Tregs led to a significant change in expression of granzyme B,
IL-10, or TGF-b, three molecules reported to play a role in Treg-
mediated suppression in vivo [21] (Figure 2). Surprisingly, CD8+
T cells from DTA-1-treated mice remained susceptible to Treg-
mediated suppression, without significant difference from those
from IgG-treated mice. We observed similar findings when DTA-1
treated CD8+ T cells were co-cultured with naı ¨ve (as opposed to
tumor-experienced) Tregs, again displaying no acquired resistance
to ex vivo suppression (data not shown). Thus, at least within the
TDLN, where initial priming of the anti-tumor effector response is
likely occurring, in vivo GITR ligation does not appear to
systemically alter the capacity of Tregs or CD8+ Teffs to suppress
or be suppressed, respectively.
GITR ligation leads to enhanced intra-tumor CD8:Treg
ratio, and greater CD8+ effector T-cell activity within the
tumor
To investigate how in vivo GITR ligation modulates T cell
subsets within the tumor, we first examined the relative intra-
tumor frequencies of Tregs and Teffs in B16-bearing hosts
following DTA-1 treatment. DTA-1 led to a significant decrease in
intra-tumor Treg frequency as a percentage of CD4+ TILs (40%
of CD4+ TIL for IgG, compared with 18% for DTA-1, p=0.02,
Figure 3A). This was accompanied by a modest increase in the
total intra-tumor CD8:CD4 T-cell ratio (0.7 for IgG compared
with 1.3 for DTA-1-treated mice, p=0.04). The net result,
therefore, was a five-fold increase in the intra-tumor CD8:Treg
ratio (13.4 for DTA-1-treated compared with 2.6 for IgG-treated
mice, p=0.05), favoring the effector population (Figure 3B).
Evaluation of absolute numbers/gram of tumors for Teffs and
Tregs paralleled the frequency data, showing decreased Tregs
Figure 2. In vivo GITR ligation does not globally alter capacity of Tregs to suppress or CD8+ Teffs to resist suppression. B16-bearing
C57BL/6 mice (n=6/group) received DTA-1 or IgG on day 4. TDLN were harvested on day 7 and CD8+ (Teff) and CD4+CD25+ (Treg) cells were isolated
by MACS beads. CFSE-labeled, IgG- or DTA-1-treated Teff were cultured with IgG- or DTA-1-treated Treg at 2:1 Teff:Treg ratio, with irradiated APCs
and anti-CD3 mAb 1 mg/ml for 4 days. A. Representative sample showing CFSE dilution in CD8+DAPI- cells.
doi:10.1371/journal.pone.0010436.g002
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(Figure S3). This demonstrated that the augmented CD8:Treg
ratio within tumors from DTA-1 treated mice resulted primarily
from changes in the Treg compartment. No significant changes in
these relative frequencies were seen in spleen or TDLN,
demonstrating a specific effect within the tumor (Figure 3B).
Interestingly, the proportion of mice with a .2-fold increase in
intra-tumor CD8:Treg ratio over the IgG control (8/13, 61%)
mirrored the percentage of mice with long-term tumor-free
survival (,60%, Figure 1A and Figure S1). This suggests that
achieving a skewed CD8:Treg ratio may be predictive of long-
term tumor control, as described recently with other immune-
modulating antibodies.[22,23]
We next investigated possible functional consequences of this
altered intra-tumor Teff:Treg ratio by exploring the effects of
GITR ligation on tumor-specific CD8+ effector cells. This was
accomplished by adoptively transferring and tracking CD8+ T
cells from Thy1.1+ pmel-1 TCR transgenic mice, which are
specific for the melanoma antigen gp100, into C57BL/6 (Thy1.2+)
mice 1 day prior to B16 challenge. GITR ligation did not
consistently increase the frequency or absolute number of donor
pmel-1 cells infiltrating the tumor (data not shown). However,
DTA-1 significantly augmented the activation of those cells that
did traffic to tumor, leading to enhanced effector function (IFN-c
secretion following gp100 peptide re-stimulation) activation
(CD44
hiCD62L
lo phenotype), and proliferation (as measured by
CFSE dilution) (Figure 3C). IFN-c-secreting pmel-1 T cells also
mobilized CD107a (LAMP-1), a surrogate for lytic degranulation
[24], demonstrating their cytolytic capacity (data not shown).
These data indicate that GITR ligation results in a more effective
intra-tumor CTL population, which may be a consequence of
both direct CD8+ T-cell co-stimulation and a more favorable local
CD8:Treg ratio.
Treatment with agonist anti-GITR mAb modulates Treg
accumulation in the tumor
Because Treg frequency was decreased only in the tumor and
not systemically, we explored the hypothesis that GITR ligation
was altering the migraton of Tregs to the tumor. Tumor-
experienced Tregs isolated from B16-bearing, Thy1.1+ mice
treated 72 hours earlier (day 4 of tumor growth) with DTA-1 or
IgG were adoptively transferred into B16-bearing Thy1.2+
recipients. Recipient mice were treated 1 day earlier with
cyclophosphamide to reduce endogenous lymphocyte populations
and aid recovery of donor cells. While DTA-1-treated and IgG-
treated Tregs distributed equally within the spleen and TDLN,
Figure 3. GITR ligation by DTA-1 limits Treg accumulation within the tumor and enhances intra-tumor CD8+ T-cell activity. A. and B.
B16-bearing mice treated with DTA-1 or IgG on day 4 had spleens, TDLN, and tumors harvested on day 10 and lymphocytes analyzed by FACS. A.
Representative FACS plots with gate frequencies, (left) and mean +SEM for frequency of Tregs within live CD4+ TIL gate (right) are shown. B. Ratio of
CD8+ to CD4+foxp3+ cells in spleen, TDLN, and tumor. *p=0.05 compared with IgG tumor. Pooled data from 3 independent experiments are shown.
C. Naı ¨ve C57BL/6 mice (n=325/group) received 4610
6 CFSE-labeled pmel-1 Thy1.1+CD8+ T cells 1 day prior to B16 inoculation. Recipients received
DTA-1 or IgG on day 4, and donor pmel-1 CD8+ cells analyzed in spleens, TDLN, and tumors on day 14. Mean frequency +SEM is shown for IFNc+
(left), activated CD44
hiCD62L
lo phenotype (center) and proliferation by CFSE dilution (right) of transferred pmel-1 T cells is shown. For IFNc recall
assay (C, left), lymphocytes from spleen, TDLN, and tumor were re-stimulated for 6 hours with irradiated, gp10025-33 peptide-pulsed EL4 cells.
Background IFNc production for lymphocytes cultured with unpulsed EL4 cells was ,1%. Over 85% of IFNc+ cells were also CD107a+ (data not
shown). * p,0.05 compared with IgG group. Representative of 3 independent experiments.
doi:10.1371/journal.pone.0010436.g003
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DTA-1-treated donor Tregs, compared to IgG-treated controls
(Figure 4A). The effect was even more dramatic when the
recipients were treated with DTA-1 following donor Treg transfer,
with a .90% reduction in donor Treg frequency within the
tumor, despite equal distribution within spleen and TDLN. To
determine if this effect was Treg-intrinsic, we repeated this
experiment using Tregs from GITR
+/+ or GITR
2/2 donors.
Tregs from GITR
2/2 mice did not show a significant block in
trafficking when transferred into DTA-1 treated animals, com-
pared to IgG controls, demonstrating a requirement for direct
GITR ligation on Tregs themselves (Figure 4B).
GITR ligation leads to loss of foxp3 expression within
intra-tumor Tregs
The above experiments suggest that one mechanism of DTA-1’s
anti-tumor efficacy may be interfering with Treg infiltration into
tumors, and imply a requirement for GITR expression on Tregs.
However, these studies examined a small transferred population in
a lympho-depleted recipient, which may not fully reflect the
biologic effects of GITR ligation under steady-state conditions. We
therefore examined other possible mechanisms that could
contribute to the DTA-1-induced decrease in intra-tumor Tregs,
including impaired proliferation, impaired survival, or loss of
foxp3 expression. We found no evidence for impaired prolifera-
tion, in fact, in vivo GITR ligation on Tregs increased their
proliferation in the spleen, TDLN, and tumor (Figure 5A),
consistent with GITR’s known co-stimulatory effects. Likewise, we
could not find evidence of impaired survival following in vivo
GITR signaling. Tregs within TDLN and tumors from DTA-1-
treated mice showed no difference in apoptosis compared with
IgG-treated controls, either by immunoflourescence (TUNEL
(Figure S4A) or flow cytometric staining (Annexin V, Figure S4B,
or activated caspase 3 (data not shown)) We did observe, however,
that the mean fluorescence intensity (MFI) of the foxp3-GFP
fusion protein was slightly lower within intra-tumor Tregs from
DTA-1-treated foxp3
GFP mice (Figure 5B), without changes seen in
spleen and TDLN (data not shown). Interestingly, there was an
inverse correlation between foxp3-GFP MFI and CD8:Treg ratio.
Mice that had the lowest expression of foxp3-GFP within intra-
tumor Tregs had the greatest corresponding CD8:Treg ratio,
while those with normal expression had ratios similar to those seen
in IgG-treated mice (Figure 5C).
Therefore, to confirm these findings and further characterize
tumor-infiltrating Tregs, we performed immunoflourescent histo-
logical analysis of B16 tumors in foxp3
GFP mice. Mice were treated
with DTA-1 on day 4 of tumor growth and tumors and TDLN
were isolated on day 10, when Treg tumor infiltration in untreated
mice begins to peak (Schaer DA, unpublished results). At this time,
the total number of GFP+ cells within the DTA-1 treated tumors
showed a ,28% decrease compared to IgG control treated mice
(mean 17.8 per high power field (hpf) for DTA-1 vs. 25/hpf for
IgG, p=0.06, Figure 6E). While this decrease was not as dramatic
as what was seen with transferred Tregs (Figure 4A), it was on par
with the reduced number of Tregs seen by FACS (Figure 3A).
More striking, however, was the finding that over 80% of Tregs in
DTA-1 treated tumors had an irregular appearance, with weak
and aberrant GFP expression that did not co-localize with nuclear
DAPI staining (Figure 6A, insert). This is in contrast to IgG tumors
where Tregs displayed ‘‘normal’’ overlay of foxp3
GFP transcription
factor with nuclear DAPI staining. The abnormal phenotype was
noted only in DTA-1-treated tumors and not IgG-treated tumors
(Figure 6B) or DTA-1-treated TDLN (Figure 6C), demonstrating a
specific effect within the tumor microenvironment. Thus, when we
quantified the numbers of ‘‘normal’’ Tregs (i.e. co-localizing GFP
and nuclear DAPI), we observed a marked decrease within DTA-
1-treated tumors (mean 4/hpf) compared with IgG-treated
controls (25/hpf, p,0.0001, Figure 6E). This represents a
,84% reduction in the numbers of ‘‘normal’’ Tregs. Recent
reports have demonstrated the plasticity of Tregs and their ability
to lose foxp3 expression under inflammatory conditions [25,26].
Therefore, we asked if the discrepancy in our data was due to loss
of foxp3 in the irregular Tregs. Co-staining for foxp3 demonstrat-
ed that these aberrant cells were all foxp3-negative (Figure 6D),
indicating that they had lost expression of the foxp3 protein. While
the irregular Tregs still maintained some GFP protein, it now was
no longer linked to foxp3 and its nuclear localization signal. The
majority of DTA-1-treated tumor sections contained only the
aberrant Tregs; however, some sections contained both normal
(foxp3+) and aberrant (foxp3-) GFP+ cells (Figure 6F), demon-
strating that this was not a staining artifact.
Figure 4. DTA-1 reduces Treg tumor trafficking in a cell intrinsic manner. A. B16-bearing Thy1.1+ donor mice were treated on day 5 with
DTA-1 (‘‘DTA-1 donor’’) or IgG (‘‘IgG donor’’), and Tregs isolated on day 8 from their spleens and TDLN were transferred (0.7610
6 per recipient) to B16-
bearing Thy1.2+ mice, treated 1 day earlier with cyclophosphamide 250 mg/kg i.p. Some recipients received Tregs from untreated B16-bearing donors
and were then treated with DTA-1 (‘‘DTA-1 recipient’’) or IgG (‘‘IgG recipient’’) 12 hours after adoptive transfer. Recipient spleens, TDLN, and tumors
were harvested 4 days after transfer. The percentage + SEM of donor (Thy1.1+CD4+foxp3+) Tregs within the total live CD4+ gate is depicted. *p=0.05
compared with IgG donor, **p=0.04 compared with IgG recipient. B. Tregs from Day 8 B16-bearing Thy1.2+ GITR
2/2 (‘‘KO donor’’) or GITR
+/+ (‘‘wt
donor’’) donors were transferred into day 8 B16-bearing Thy1.1+ recipients treated 1 day earlier with cyclophosphamide 250 mg/kg i.p. Recipients
received DTA-1 or IgG 12 hours post-transfer, and spleens, TDLN, and tumors were harvested 4 days later. The % + SEM of donor (Thy1.2+CD4+foxp3+)
Tregs within the total live CD4+ gate is depicted. *p=0.07 compared with wt donor + IgG, **p=0.24 compared with wt donor + IgG.
doi:10.1371/journal.pone.0010436.g004
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tumor infiltration and loss of foxp3 expression to the decreased
intra-tumor accumulation of Tregs, we repeated the adoptive
transfer experiments described in Figure 4 using highly purified
(.99% CD4+GFP+, 93% foxp3+ (data not shown)), FACS-sorted
donor Tregs from foxp3
GFP mice, in an attempt to track Tregs that
become foxp3-negative within the tumor. By gating on donor cells
using a congenic marker and assessing dual expression of foxp3
and GFP, we found both decreased Treg infiltration and loss of
foxp3 expression within the tumors of DTA-1-treated recipients
(Figure 7A), implying that both of these mechanisms are playing a
role in this phenomenon. Interestingly, a significant minority of
CD4+GFP+ donor cells entering control IgG-treated tumors also
became foxp3-negative (and GFP-negative), as described previ-
ously for Tregs transferred into lymphopenic hosts [27,28], which
is likely related to the pre-treatment of recipients with cyclophos-
phamide 1 day prior to transfer. This population, however, was
significantly increased following in vivo GITR ligation (mean % of
foxp3+ donors becoming foxp3- =78% for DTA-1 vs. 34% for
IgG, p=0.001, Figure 7A), demonstrating an additional effect of
GITR ligation. We were unable, at least by FACS analysis, to
identify the aberrant or ‘‘transitioning’’ GFP+foxp3- cells in these
adoptive transfer experiments. As Tregs require continued nuclear
foxp3 expression to remain suppressive [29], it is possible that
these foxp3-,‘‘former’’ Tregs have lost regulatory function. Thus,
in addition to impairing tumor infiltration, a mechanism by which
GITR ligation alters the Teff:Treg balance within the tumor may
be alteration of the lineage stability of intra-tumor Tregs.
Maximal anti-tumor effect of agonist anti-GITR mAb
requires GITR expression by both effector and regulatory
T cells
Finally, because of these myriad effects on intra-tumor Tregs, as
well as current (Figure 3C) and prior [15,16,17] data showing
enhancement of Teff function, we attempted to confirm that
Figure 5. Intra-tumor Tregs show increased proliferation and lower Foxp3GFP MFI after DTA-1 treatment. A. Representative Ki67
expression within live CD4+foxp3+ cells isolated from day 10 B16-bearing C57BL/6 mice treated with DTA-1 or IgG on day 4. B. and C. TIL were
isolated from day 10 B16-bearing foxp3
GFP mice (n=5/group) treated with DTA-1 or IgG on day 4 and examined by FACS. B. Mean fluorescence
intensity (MFI) of GFP on live intra-tumor CD4+GFP+ cells. C. Intra-tumor CD8:Treg ratio of DTA-1- and IgG treated mouse in (B) is plotted against its
foxp3
GFP MFI, demonstrating a significant inverse correlation between Teff:Treg ratio and foxp3GFP MFI in DTA-1 treated mice only (p=0.03). Data
are representative of 3 independent experiments.
doi:10.1371/journal.pone.0010436.g005
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bearing foxp3
GFP mice (n=4/group) treated with DTA-1 or IgG on day 4. Tumor sections were stained with anti-CD8 (magenta), anti-CD31 (red, to visualize
endothelium), and DAPI (blue, for nuclear staining) and analyzed by immunofluorescence. A. DTA-1-treated tumor showing Tregs with irregular borders,
weaker foxp3/GFP+ signal, and non-nuclear GFP localization (inset). B. IgG-treated tumor showing Tregs with foxp3 protein (GFP+, green) co-localizing with
nucleus. C. DTA-1- and IgG-treated TDLN demonstrating intact foxp3+cells. D. Left, top: DTA1-treated tumor co-stained with anti-foxp3. Note lack of foxp3 co-
staining in cells with abnormal cytoplasmic GFP signal, compared with overlapping nuclear foxp3 and GFP in IgG-treated intra-tumor Tregs (left, bottom) or
DTA-1- or IgG-treated TDLN (right). Scale for all images is show in A (bar=25 mm). E. The number of GFP+ cells per high-powered field (hpf) were counted,
regardless of either intensity or localization (‘‘total’’, left graph) or only with bright nuclear GFP signal (i.e. co-localizing with DAPI) (‘‘nuclear GFP,’’ right graph).
Pooled data from a total of 46 (IgG) or 48 (DTA-1) examined hpf (10–12 hpf per tumor64 tumors/group) are shown. F. Although the majority of DTA-1 treated
Tregs have an ‘‘abnormal’’ GFP+ foxp3- phenotype, ‘‘intact’’ and ‘‘abnormal’’ Tregs can be found together within a minority of DTA-1 treated tumor sections.
doi:10.1371/journal.pone.0010436.g006
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protective effect of DTA-1. Therefore, we reconstituted RAG1
2/2
mice with different combinations of Teffs and Tregs isolated from
either GITR
2/2 or GITR
+/+ littermates, challenged with B16,
and treated with DTA-1 or IgG on day 4 of tumor growth (Figure
S5). Although we did not see full protection with DTA-1 in this
RAG1
2/2 reconstitution system, there was a statistically signifi-
cant delay in tumor growth seen only when both Teff and Treg
were GITR +/+ (Figure 7B). Lack of GITR on either population
led to an attenuated effect, while lack of GITR on both
populations abrogated any protective effect. Taken together, these
findings provide further evidence that agonist anti-GITR mAb is
modulating the activity of both Teffs and Tregs to effect tumor
immunity.
Discussion
Although prior studies have demonstrated that in vivo GITR
ligation results in anti-tumor effects, the exact mechanisms
involved remain elusive. This study sought to determine whether
GITR ligation on Teffs, Tregs, or both was primarily responsible
for these anti-tumor effects, and explore how these subsets were
Figure 7. DTA-1-induces foxp3 loss in intra-tumor Tregs after transfer, and the effects of DTA-1 require GITR expression on effector
and regulatory T cells. A. CD4+GFP+ Tregs isolated from spleens and TDLN of B16-bearing CD45.2+ foxp3
gfp donor mice on day 8 after tumor
challenge were transferred (0.7610
6 per recipient) into B16-bearing CD45.1+ mice treated with cyclophosphamide and DTA-1 or IgG, as described in
Figure 4. Tumor-infiltrating lymphocytes were isolated 2–3 days later and CD45.2+ donor T cells were assessed for their level of foxp3 and GFP
expression by FACS. Left: The % + SEM of donor (CD45.2+) Tregs found within the total live CD4+ gate is depicted, along with relative proportions
that became foxp3-negative. Donor Tregs within DTA-1-treated tumors showed a significantly greater reduction in foxp3 expression (p=0.001)
Right:. Representative FACS plots gated on live CD45.2+CD4+ TIL. Data are pooled (n=7 per group) from 2 independent experiments. B RAG1
2/2
mice (n=529/group) were reconstituted with indicated combinations of effector (Te: CD8+ and CD4+CD25-) and regulatory (Tr: CD4+CD25+) T cells
from GITR
2/2 (2) or GITR
+/+ (+) littermates (See Figure S5 for schema). After 4 weeks, mice were challenged with B16 and treated with DTA-1 or IgG
on day 4. At 18 and 22 days post-challenge, when all tumor-free survival is lost in WT untreated animals (Figure 1A), mean diameter of the Te+/Tr+
(DTA1) group was significantly different from all other groups. (p,0.05; two-tailed student’s t-test). Data are pooled from 2 independent experiments.
doi:10.1371/journal.pone.0010436.g007
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using a fibrosarcoma model [15], we found that GITR ligation
was more effective after several days of B16 melanoma growth
compared with day 0. This suggested a requirement for initial
priming of the immune response in order to induce upregulation
of GITR on activated cells. The need for activation before
effective GITR ligation is also consistent with our prior study
combining DTA-1 with xenogeneic DNA vaccination, in which
DTA-1 augmented CD8+ responses and tumor protection only
when administered with the second vaccination, and was
ineffective when given prior to the initial priming vaccine.[16]
During optimal therapy with DTA-1, it became apparent that
Treg tumor infiltration was dramatically decreased compared to
untreated animals. This resulted in an enhanced intra-tumor
CD8:Treg ratio, without significant changes in the spleen or
TDLN. A similar skewed ratio has recently been reported with an
agonist anti-OX40 mAb, as well as antagonist anti-CTLA4 mAb,
suggesting that an altered intra-tumor Teff:Treg ratio may be
predictive of anti-tumor activity of these immune-modulating
approaches[22,23,30,31]. Regardless of its prognostic implication,
the reduced Treg infiltration without major changes in total CD8+
T cell numbers was our initial evidence that a Treg-intrinsic effect
was occurring during DTA-1 treatment.
In exploring the effects of DTA-1 on Tregs further, we
discovered that the altered CD8:Treg ratio following GITR
ligation was due both to decreased Treg tumor infiltration and to
loss of foxp3 within Tregs that did infiltrate the tumor.
Transferring tumor-experienced Tregs into DTA-1-treated, tu-
mor-bearing hosts showed that this effect was dependent on Treg
GITR expression, as GITR
2/2 Tregs did not show significant
changes in tumor infiltration. Regulation of Treg trafficking to
peripheral sites is complex, with a host of different integrins and
chemokine receptors being implicated [32,33]. CD103 (aE),
CCR7, and CD62L (L-selectin) are involved in Treg trafficking
from lymph nodes to inflamed sites, with CD103+CCR7-CD62L-
Tregs most capable of homing to and suppressing peripheral
inflammation [34,35]. We did not see significant changes in
CD103, CCR7 or CD62L expression on TDLN Tregs 48 or
72 hours following in vivo DTA-1 treatment (Figure S6). In
addition, the chemokine receptor CCR4 (specific for CCL17 and
CCL22) has been specifically implicated in Treg migration into
tumors [36,37], and we are currently examining alterations in the
levels of this and other chemokine receptors on Tregs following
GITR ligation in vitro and in vivo.
By histology we observed that most Tregs that do enter the
tumor lose foxp3 expression, with some residual GFP expression
now localized to the cytosol. In fact, repeating the transfer
experiment with a highly-purified Treg population from foxp3
GFP
mice confirmed the DTA-1-induced intra-tumor foxp3 loss in this
transferred population as well. Whether this loss of foxp3 protein is
due to decreased expression, increased degradation, or some
combination of the above is not clear. The plasticity of both
naturally-arising and induced CD4+foxp3+ Tregs has recently
been documented in several studies, with loss of foxp3 expression
and suppressive function occurring during conditions of lympho-
penia or inflammation/autoimmunity, in some cases even
accompanied by gain of effector function [25,26,27,28,38]. Treg
lineage stability may be regulated in part through the integration
of external stimuli which either promote/maintain (e.g. IL-2, IL-
10, TGF-b) or decrease (e.g. IL-6) foxp3 expression, through
modulation of signaling pathways and altered methylation of the
foxp3 locus [39,40]. Interestingly, Luo et al recently reported that
TGF-b1-mediated induction of foxp3 in CD4+CD25- cells was
due to inhibition of phospho-ERK and down-regulation of DNA
methyltransferases, leading to demethylation of the foxp3
promoter [41]. Signaling through GITR is known to activate the
MAP kinase pathway and induce ERK phosphorylation [4,42,43].
Thus, GITR ligation may antagonize the effects of TGF-b on
pERK and inhibit downstream signaling which normally induces
foxp3 gene expression. In support of this, we have found that in
vitro GITR ligation is able to block TGF-b-mediated up-
regulation of foxp3 in activated CD4+foxp3- T cells (Figure S7),
suggesting an effect on gene expression. Whether this mechanism,
likely in concert with other inflammatory stimuli present within
the tumor microenvironment, plays a role in the selective loss of
foxp3 observed in tumor-infiltrating Tregs is currently under
investigation.
Despite this effect in the tumor, DTA-1 did not modulate the ex
vivo suppressive capacity of Tregs isolated from TDLN, consistent
with prior ex vivo [17,18] and in vitro [6,44] studies. In all of these
studies, Treg suppressive ability was maintained during GITR
ligation, and collectively these data refute the argument that GITR
ligation globally makes Tregs unable to suppress. Still, it remains
possible that intra-tumor Tregs, which lose foxp3 expression, have
diminished suppressive capacity. This possibility is supported by
recent data demonstrating that Tregs require constant foxp3
expression for the continued expression of suppressive genes, and
for the repression of inflammatory genes as well.[29] Unfortu-
nately, we were unable to test the ex vivo suppressive capacity of
these ‘‘former’’ Tregs, as the yield of purified live GFP+ TIL
isolated from DTA-1-treated, B16-bearing foxp3
GFP mice was
always too low after FACS-sorting (data not shown). Thus, this
question remains open for now.
Somewhat surprisingly, we did not find that in vivo GITR
ligation in our B16 model made CD8+ Teffs from TDLN resistant
to Treg-mediated suppression ex vivo, in contrast to prior
observations with CD4+ [6,17] or CD8+ Teffs [19]. One
explanation for this discrepancy may be that we isolated CD8+
T cells from the TDLN 72 hours after DTA-1. Since CD8+ T cells
are less responsive in general to GITR signaling than CD4+ T
cells [3,6,10,11], it is possible that the level of GITR signaling
required for ‘‘resistance’’ to Tregs had waned by the time these
cells were activated ex vivo. In addition, we used bulk CD8+ Teffs
isolated from TDLN, only a minority of which were likely
activated by tumor antigens and therefore amenable to co-
stimulation by DTA-1. In contrast, the study by Nishikawa et al
demonstrating generation of ‘‘Treg-resistant’’ CD8+ cells used
activated, tetramer-purified, antigen-specific CD8+ T cells in their
suppression assays.[19] Based on these data, it is possible that a
population of activated, tumor-specific CD8+ T cells from DTA-1-
treated B16-bearing TDLN might be similarly ‘‘Treg-resistant.’’
While we did not demonstrate that GITR ligation directly
modulated suppression or resistance to suppression, we did
observe a reproducible increase in the intra-tumor effector
function of tumor specific pmel-1 T cells. Therefore, even if
Tregs still retain suppressive capacity following GITR ligation,
their relative numerical disadvantage in the tumor may render
them less effective overall.
Considering our evidence that DTA-1 directly modulated Tregs
as well as Teffs, we reconstituted RAG1
2/2 mice with GITR
2/2
or GITR
+/+ Teffs and Tregs, to confirm which cell types were able
to respond to GITR ligation. While the anti-tumor effect of DTA-
1 in this system was modest, the delay in tumor growth was
reduced if either Tregs or Teffs lacked GITR, and was non-
existent if both subsets were GITR-negative. It is possible that the
weakened effect of DTA-1 was due to inadequate peripheral
reconstitution. Alternatively, there could be a contributing role for
GITR ligation on B cells or NK-T cells, both of which were absent
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2/2 mice and have been reported recently to have
augmented activation with GITR co-stimulation.[17,45]. Regard-
less, these data suggest that GITR must be present on both Treg
and Teff populations for the full anti-tumor effects of DTA-1.
In conclusion, a single dose of agonist anti-GITR mAb can
induce T-cell-mediated rejection of an aggressive, poorly immu-
nogenic tumor. Additionally, our data supports the idea that DTA-
1 modulates both Teffs and Tregs during therapy. GITR ligation
on Tregs appears to cause impaired accumulation within the
tumor through Treg lineage instability and a block of trafficking.
This leads to greater intra-tumor Teff:Treg ratios and more potent
Teff activity. Furthermore, those Tregs which do traffic to the
tumor are likely limited in their suppressive capacity as denoted by
loss of continued nuclear foxp3 protein expression. Importantly,
the preservation of global Treg function and limitation of this
skewed ratio to the tumor may make widespread loss of tolerance
and autoimmune consequences with in vivo GITR ligation less
likely. These data provide further support for the development of
this strategy as a therapeutic approach to human cancer.
Materials and Methods
Ethics Statement
Mice were maintained according to NIH Animal Care
guidelines, under a protocol 96-04-017 approved by the MSKCC
Institutional Animal Care Committee.
Mice
C57BL/6 Thy1.2+ and Thy1.1+ mice were obtained from
Jackson Laboratory (Bar Harbor, ME). Thy1.1+ pmel-1 T-cell
receptor transgenic mice have been reported.[46] foxp3
GFP knock-
in mice were a gift from Dr. A. Rudensky (MSKCC, NY, NY).[20]
GITR
2/2 and GITR
+/+ littermates (Sv129 x C57BL/6 back-
ground)[47] were a gift from Dr. P.P. Pandolfi (MSKCC, NY, NY)
and were backcrossed .10 generations onto C57BL/6 back-
ground using a speed congenic system[48].
Cell lines and tumor challenge
B16F10/LM3 (hereafter called B16) is derived from the B16F10
line provided by I. Fidler (M.D. Anderson Cancer Center,
Houston, TX). EL4, (American Type Culture Collection, ATCC
Number: TIB-39, Manassas, VA), C57BL/6 lymphoma cell line
was used as an antigen-presenting cell in intracellular cytokine
assays. Cell lines were cultured as described.[49] For tumor-free
survival experiments, 50,000 B16 cells were injected intradermally
in serum-free RPMI media, and tumor diameters were measured
with calipers every 2–3 days. For experiments requiring recovery
of tumor-infiltrating lymphocytes (TIL), 500,000 B16 cells in
growth factor-reduced, phenol red-free Matrigel (BD Biosciences)
were injected subcutaneously.
Lymphocyte isolation
Spleens, tumor-draining inguinal lymph nodes, and tumors
were homogenized through 0.22 mm strainers to produce single
cell suspensions. RBCs were lysed from spleens using an
ammonium chloride lysis buffer. TILs were isolated from tumor
suspensions by density gradient centrifugation using Percoll (GE
Healthcare, Piscataway, NJ). Briefly, cell pellets were suspended in
80% Percoll, overlayed with 40% Percoll, and centrifuged at
20006g for 30 minutes. Cells at the interface were collected,
washed, and used for FACS or functional assays. Intracellular
cytokine assays for expression of IFN-c and CD107a following
peptide restimulation were performed as reported.[16]
Isolation of CD8+, CD4+foxp3+, and CD4+foxp3- cells from
foxp3
GFP mice was performed on a Cytomation MoFlo cell sorter.
Isolation of CD8+, CD4+CD25+, and CD4+CD25- cells from
other mouse strains was performed using MACS microbead
separation kits (Miltenyi Biotec Inc., Auburn, CA). pmel-1 CD8+
cells were labeled with CFSE 2.5 mM prior to adoptive transfer.
Transferred cells were injected intravenously by tail vein in 200 ml
sterile PBS. For some adoptive transfer experiments, recipients
were pre-treated with cyclophosphamide (Sigma-Aldrich) 250 mg/
kg in 500 ml sterile PBS intraperitoneally one day prior to transfer.
Antibodies and FACS analysis
The DTA-1 hybridoma, from S. Sakaguchi (Kyoto University,
Kyoto, Japan), and the OX86 hybridoma, from A. Weinberg
(Earle Chiles Research Institute, Portland, OR), were used to
produce agonist anti-GITR and anti-OX40 mAb, respectively, by
the MSKCC Monoclonal Antibody Core Facility. One mg
affinity-purified DTA-1 in 500 mL PBS was injected intraperito-
neally. Purified Rat IgG (Sigma-Aldrich) was used as a control.
Foxp3 staining was performed using the Mouse Regulatory T-Cell
Staining Kit (eBioscience, San Diego, CA). Other flow cytometry
antibodies were from BD Biosciences (San Jose, CA). hgp10025-33-
D
b-tetramer, containing the D
b epitope KVPRNQDWL, has been
described.[16] For fixed/permeablized samples, LIVE/DEADH
Fixable Dead Cell Stain Kit (Invitrogen, Carsbad, CA) was used to
identify dead cells; for other samples DAPI was used. Samples
were run on a BD 4-color FACSCalibur or 12-color LSRII
cytometer, and were analyzed using FlowJo (Treestar, San Carlos,
CA).
Immunofluorescence
B16-matrigel tumor samples were harvested on day 10 and fresh
frozen tissue was embedded in OCT. Sequential 5 mm sections
were collected and stained with anti-CD31 biotin (BD Pharmin-
gen), anti-CD8 Alexa fluor 657 (Caltag/Invitrogen), anti-foxp3
APC (ebiosicence), anti-Caspase 3 (BD Pharmingen) and DAPI for
nuclear stain. TUNEL staining (TdT and biotin-dUTP from
Roche Diagnostics Corp.) was performed after proteinase K
digestion (Sigma) and detected using Alexa-633 Avidin (Molecular
Probes). Images were acquired with a Leica upright confocal
microscope using 20X objective at 204862048 resolution.
Acquisition was performed using IgG-treated LN sections to set
PMT detector settings at non-saturating conditions, with back-
ground levels set using isotype control or secondary antibody
alone. Detector voltages were then maintained for each staining
condition across all sections.
Treg suppression assay
10
5 CD8+ Teff were labeled with 1.25 mM CFSE and cultured
with CD4+foxp3+ cells (FACS-sorted from foxp3
GFP mice) or
CD4+CD25+ cells (MACS-selected from C57BL/6 mice) at
indicated ratios, along with 10
5 T-cell-depleted, irradiated (444
cGy) splenocytes and 1 mg/ml anti-CD3 mAb. After 4 days, cells
were harvested, stained with anti-CD8 and DAPI and analyzed by
FACS.
Quantitative real time PCR
Total RNA was extracted from FACS-sorted Tregs using RNeasy
Micro Kit (Qiagen, CA) and cDNA synthesized using High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
CA) according to manufacturer’s instructions. All primers and
probes were from TaqManH Gene Expression Assays (Applied
Biosystems). Real-time PCR reactions were prepared with 4 ul
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TaqMan probe mixture, 12.5 ul of 26TaqMan Universal PCR
Master Mix and 7.25 ul of DNase/Rnase-free water. All amplifi-
cations were done using ABI 7500 Real Time PCR system. Each
gene was amplified in triplicate and cDNA concentration differences
were normalized to GAPDH. Relative gene expression changes of
the target genes in DTA-1-treated group compared to IgG-treated
group were calculated by 2-ddCt method (25) using average Ct
(threshold cycle) of triplicates from the IgG-treated group as a
calibrator. Fold increase or decrease in gene expression was
calculated and the values were log10-transformed before plotting.
Statistical analysis
Differences in long-term tumor-free survival were evaluated by
log rank analysis of Kaplan-Meier survival curves (GraphPad
Prism 4.0). Statistical differences between groups were determined
by analyzing means + standard errors of replicate mice or wells by
two-tailed Student’s t test (GraphPad Prism 4.0).
Supporting Information
Figure S1 DTA-1 induces rejection of B16 melanoma most
effectively at day 4. C57BL/6 mice were challenged with 50,000
B16 cells intradermally and treated with DTA-1 or Rat IgG on
indicated days. Pooled data from 5 experiments (n=30250 total
mice/group). Mice alive at day 60 without tumor were considered
long-term tumor-free survivors.
Found at: doi:10.1371/journal.pone.0010436.s001 (0.14 MB TIF)
Figure S2 GITR ligation does not decrease Treg expression of
Granzyme B, IL10, or TGF-b. For in vitro analysis, purified
CD4+foxp3+ cells (from spleens + LN of naı ¨ve foxp3GFP mice)
were treated with anti-CD3 mAb 1 mg/ml, anti-CD28 mAb 1 mg/
ml, and DTA-1 or Rat IgG 10 mg/ml for 48 hours, followed by
RNA extraction and quantitative real-time PCR as per Supple-
mental Methods below. For in vivo analysis, RNA was extracted
from CD4+foxp3+ cells purified from TDLN of day 10 B16-
bearing foxp3GFP mice treated 3 days earlier with DTA-1 or IgG
1 mg i.p. The relative change (on log10 scale) in gene expression
(normalized to GAPDH) for DTA-1-treated Tregs compared to
IgG-treated Tregs is depicted.
Found at: doi:10.1371/journal.pone.0010436.s002 (0.13 MB TIF)
Figure S3 No changes seen in absolute number of CD8 T cells/
gram of tumor after DTA-1 treatment. Representative counts from
3 independent experiments showing numbers of T cells per gram
of tumor. CD8 T cells are gated on CD45+ CD8+ and Tregs are
gated on CD45+CD4+,foxp3+ inside the live gate from tumors, 10
days after B16 inoculation,(6 days post DTA-1 treatment).
Found at: doi:10.1371/journal.pone.0010436.s003 (0.19 MB TIF)
Figure S4 Abnormal GFP+ Tregs within DTA-1-treated tumors
are not undergoing apoptosis. Day 10 B16-matrigel tumors from
foxp3GFP mice treated with 1 mg DTA-1 or IgG on day 4 were
harvested and processed for TUNEL staining (A) or flow
cytometry (B) as per Methods. A) Representative images show
lack of TUNEL positive staining of irregular Tregs (arrows) inside
DTA1 treated tumors. B) Representative staining of live (DAPI-)
tumor-infiltrating Tregs (CD4+GFP+) show no difference in
frequency of apoptotic (Annexin V+) cells between DTA-1 and
IgG-treated tumors. Gate placement based on fluorescence
intensity of stained cells without addition of Annexin V.
Found at: doi:10.1371/journal.pone.0010436.s004 (3.93 MB TIF)
Figure S5 Schema for reconstitution of RAG12/2 mice with
GITR2/2 or GITR+/+ effector (Teff) or regulatory (Treg) T
cells.
Found at: doi:10.1371/journal.pone.0010436.s005 (0.18 MB TIF)
Figure S6 In vivo GITR ligation does not alter surface
expression of CD103, CD62L, or CCR7 on Tregs within
tumor-draining lymph nodes. B16-bearing C57BL/6 mice were
treated with DTA-1 or IgG 1 mg on day 4 and tumor-draining
lymph nodes harvested 48 hours later. Isolated lymphocytes were
stained for FACS. Expression of indicated molecules on gated live
CD4+foxp3+ Tregs from representative mice are depicted. Similar
findings were observed 72 hours after DTA-1 or IgG treatment
(data not shown).
Found at: doi:10.1371/journal.pone.0010436.s006 (0.30 MB TIF)
Figure S7 GITR ligation blocks TGF-b-mediated in vitro
peripheral conversion to induced Tregs. 56104 CD4+foxp3- cells
(FACS-sorted from naive foxp3GFP splenocytes) were cultured for
5 days at 37uC with 1.56105 irradiated T-cell depleted
splenocytes, 0.1 mg/ml anti-CD3 mAb, 1 mg/ml anti-CD28
mAb, and indicated concentrations of IgG, DTA-1, or OX86
(agonist anti-OX40 mAb). 40 U IL-2 and 5 ng/ml TGF-b1 was
added to each well after 48 hours in culture. After a total of 5 days
incubation, cells were harvested, stained with anti-CD4 and DAPI
and analyzed by FACS. The % foxp3+GFP+ from gated
CD4+DAPI- are shown. Similar findings were seen using anti-
CD3 mAb at 0.01 or 1 mg/ml (data not shown). Data are from 1 of
3 representative experiments.
Found at: doi:10.1371/journal.pone.0010436.s007 (0.43 MB TIF)
Acknowledgments
The authors wish to thank Hong Zhong and Andre Burey for their
management of mouse colonies. Dr. Francesca Avogadri, Dr. Karim
Lakehal for assistance with sample preparation and T cell transfers, along
with input regarding experimental design. Dr. Li-Fan Lu, and Dr.
Ashutosh Chaudhry for input regarding experimental design. MSKCC
Molecular Cytology Core Facility for assistance with confocal microscopy.
Dr. Stephanie Terzulli, Dr. Alan B Frey and Dr. Li-Fan Lu for their
comments and careful reading and editing of this manuscript.
Author Contributions
Conceived and designed the experiments: ADC DAS TM ANH JDW.
Performed the experiments: ADC DAS CL YL DHC SCK AD GAR FD.
Analyzed the data: ADC DAS CL SCK MP TM ANH. Contributed
reagents/materials/analysis tools: TM. Wrote the paper: ADC DAS.
References
1. Nocentini G, Riccardi C (2005) GITR: a multifaceted regulator of immunity
belonging to the tumor necrosis factor receptor superfamily. Eur J Immunol 35:
1016–1022.
2. Kohm AP, Williams JS, Miller SD (2004) Cutting edge: ligation of the
glucocorticoid-induced TNF receptor enhances autoreactive CD4+ T cell
activation and experimental autoimmune encephalomyelitis. J Immunol 172:
4686–4690.
3. Kanamaru F, Youngnak P, Hashiguchi M, Nishioka T, Takahashi T, et al.
(2004) Costimulation via glucocorticoid-induced TNF receptor in both
conventional and CD25+ regulatory CD4+ T cells. J Immunol 172: 7306–7314.
4. Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, et al. (2004) GITR, a
member of the TNF receptor superfamily, is costimulatory to mouse T
lymphocyte subpopulations. Eur J Immunol 34: 613–622.
5. Tone M, Tone Y, Adams E, Yates SF, Frewin MR, et al. (2003) Mouse
glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for
T cells. Proc Natl Acad Sci U S A 100: 15059–15064.
6. Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, et al. (2004)
Engagement of glucocorticoid-induced TNFR family-related receptor on
effector T cells by its ligand mediates resistance to suppression by CD4+CD25+
T cells. J Immunol 173: 5008–5020.
Targeting GITR on Tregs
PLoS ONE | www.plosone.org 11 May 2010 | Volume 5 | Issue 5 | e104367. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, et al. (2002)
CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a
functional role for the glucocorticoid-induced TNF receptor. Immunity 16:
311–323.
8. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S (2002) Stimulation
of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-
tolerance. Nat Immunol 3: 135–142.
9. Suri A, Shimizu J, Katz JD, Sakaguchi S, Unanue ER, et al. (2004) Regulation
of autoimmune diabetes by non-islet-specific T cells - a role for the
glucocorticoid-induced TNF receptor. Eur J Immunol 34: 447–454.
10. Muriglan SJ, Ramirez-Montagut T, Alpdogan O, Van Huystee TW, Eng JM,
et al. (2004) GITR activation induces an opposite effect on alloreactive CD4(+)
and CD8(+) T cells in graft-versus-host disease. J Exp Med 200: 149–157.
11. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, et al. (2005)
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory
activity: a novel regulatory role for OX40 and its comparison with GITR. Blood
105: 2845–2851.
12. Dittmer U, He H, Messer RJ, Schimmer S, Olbrich AR, et al. (2004) Functional
impairment of CD8(+) T cells by regulatory T cells during persistent retroviral
infection. Immunity 20: 293–303.
13. Suvas S, Kim B, Sarangi PP, Tone M, Waldmann H, et al. (2005) In vivo
kinetics of GITR and GITR ligand expression and their functional significance
in regulating viral immunopathology. J Virol 79: 11935–11942.
14. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, et al.
(2004) Concomitant tumor immunity to a poorly immunogenic melanoma is
prevented by regulatory T cells. J Exp Med 200: 771–782.
15. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, et al. (2005) Treatment
of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-
infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 202: 885–891.
16. Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, et al. (2006) Agonist
Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and
Tumor Immunity. Cancer Res 66: 4904–4912.
17. Zhou P, L’Italien L, Hodges D, Schebye XM (2007) Pivotal roles of CD4+
effector T cells in mediating agonistic anti-GITR mAb-induced-immune
activation and tumor immunity in CT26 tumors. J Immunol 179: 7365–7375.
18. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH,
Kochman AA, et al. (2006) Glucocorticoid-Induced TNF Receptor Family
Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma
Differentiation Antigens and Enhances Antitumor Immunity. J Immunol 176:
6434–6442.
19. Nishikawa H, Kato T, Hirayama M, Orito Y, Sato E, et al. (2008) Regulatory T
cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis
factor receptor signaling. Cancer Res 68: 5948–5954.
20. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, et al. (2005)
Regulatory T cell lineage specification by the forkhead transcription factor
foxp3. Immunity 22: 329–341.
21. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work.
Nat Rev Immunol 8: 523–532.
22. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, et al. (2008) OX40
agonist therapy enhances CD8 infiltration and decreases immune suppression in
the tumor. Cancer Res 68: 5206–5215.
23. Quezada SA, Peggs KS, Curran MA, Allison JP (2006) CTLA4 blockade and
GM-CSF combination immunotherapy alters the intratumor balance of effector
and regulatory T cells. J Clin Invest 116: 1935–1945.
24. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003)
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow
cytometric assay for degranulation. J Immunol Methods 281: 65–78.
25. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, et al. (2009) Interleukin
10 acts on regulatory T cells to maintain expression of the transcription factor
Foxp3 and suppressive function in mice with colitis. Nat Immunol 10:
1178–1184.
26. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M,
et al. (2009) Instability of the transcription factor Foxp3 leads to the generation
of pathogenic memory T cells in vivo. Nat Immunol 10: 1000–1007.
27. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, et al. (2007)
Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445:
771–775.
28. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, et al.
(2009) Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell
lineage and an uncommitted minor population retaining plasticity. Proc Natl
Acad Sci U S A 106: 1903–1908.
29. Williams LM, Rudensky AY (2007) Maintenance of the Foxp3-dependent
developmental program in mature regulatory T cells requires continued
expression of Foxp3. Nat Immunol 8: 277–284.
30. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP (2009) Blockade
of CTLA-4 on both effector and regulatory T cell compartments contributes to
the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206: 1717–1725.
31. Piconese S, Valzasina B, Colombo MP (2008) OX40 triggering blocks
suppression by regulatory T cells and facilitates tumor rejection. J Exp Med
205: 825–839.
32. Kim CH (2006) Migration and function of FoxP3+ regulatory T cells in the
hematolymphoid system. Exp Hematol 34: 1033–1040.
33. Wei S, Kryczek I, Zou W (2006) Regulatory T-cell compartmentalization and
trafficking. Blood 108: 426–431.
34. Huehn J, Siegmund K, Lehmann JC, Siewert C, Haubold U, et al. (2004)
Developmental stage, phenotype, and migration distinguish naive- and effector/
memory-like CD4+ regulatory T cells. J Exp Med 199: 303–313.
35. Siegmund K, Feuerer M, Siewert C, Ghani S, Haubold U, et al. (2005)
Migration matters: regulatory T-cell compartmentalization determines suppres-
sive activity in vivo. Blood 106: 3097–3104.
36. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific
recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege
and predicts reduced survival. Nat Med 10: 942–949.
37. Haas J, Schopp L, Storch-Hagenlocher B, Fritzsching B, Jacobi C, et al. (2008)
Specific recruitment of regulatory T cells into the CSF in lymphomatous and
carcinomatous meningitis. Blood 111: 761–766.
38. Wan YY, Flavell RA (2007) Regulatory T-cell functions are subverted and
converted owing to attenuated Foxp3 expression. Nature 445: 766–770.
39. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA (2009) Plasticity of CD4(+)
FoxP3(+) T cells. Curr Opin Immunol 21: 281–285.
40. Lal G, Zhang N, van der Touw W, Ding Y, Ju W, et al. (2009) Epigenetic
regulation of Foxp3 expression in regulatory T cells by DNA methylation.
J Immunol 182: 259–273.
41. Luo X, Zhang Q, Liu V, Xia Z, Pothoven KL, et al. (2008) Cutting edge: TGF-
beta-induced expression of Foxp3 in T cells is mediated through inactivation of
ERK. J Immunol 180: 2757–2761.
42. Esparza EM, Arch RH (2005) Glucocorticoid-Induced TNF Receptor Functions
as a Costimulatory Receptor That Promotes Survival in Early Phases of T Cell
Activation. J Immunol 174: 7869–7874.
43. Zhou Z, Song X, Berezov A, Zhang G, Li Y, et al. (2008) Human
glucocorticoid-induced TNF receptor ligand regulates its signaling activity
through multiple oligomerization states. Proc Natl Acad Sci U S A 105:
5465–5470.
44. Igarashi H, Cao Y, Iwai H, Piao J, Kamimura Y, et al. (2008) GITR ligand-
costimulation activates effector and regulatory functions of CD4+ T cells.
Biochem Biophys Res Commun 369: 1134–1138.
45. Kim HJ, Kim HY, Kim BK, Kim S, Chung DH (2006) Engagement of
glucocorticoid-induced TNF receptor costimulates NKT cell activation in vitro
and in vivo. J Immunol 176: 3507–3515.
46. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, et al.
(2003) Tumor regression and autoimmunity after reversal of a functionally
tolerant state of self-reactive CD8+ T cells. J Exp Med 198: 569–580.
47. Ronchetti S, Nocentini G, Riccardi C, Pandolfi PP (2002) Role of GITR in
activation response of T lymphocytes. Blood 100: 350–352.
48. Wakeland E, Morel L, Achey K, Yui M, Longmate J (1997) Speed congenics: a
classic technique in the fast lane (relatively speaking). Immunology Today 18:
472–477.
49. Hara I, Takechi Y, Houghton AN (1995) Implicating a role for immune
recognition of self in tumor rejection: passive immunization against the brown
locus protein. J Exp Med 182: 1609–1614.
Targeting GITR on Tregs
PLoS ONE | www.plosone.org 12 May 2010 | Volume 5 | Issue 5 | e10436